RxDoctor Payments Data

Nicole Stevenson

Family · Petersburg, INNPI 1063727204

Payments from drug & device makers

$6,698in general payments, 2019–2025

Across 426 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$851
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$564
  • Lilly USA, LLC$499
  • Corium, LLC$429
  • Ironshore Pharmaceuticals Inc.$394
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,60499%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,698 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$2,641
Medicare patients
37
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol114$83,701
OtezlaApremilast12$57,891
VraylarCariprazine Hcl20$33,423
MounjaroTirzepatide20$25,080
OzempicSemaglutide20$22,480
EliquisApixaban22$19,882
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,166
JardianceEmpagliflozin22$16,813
LinzessLinaclotide15$14,314
Repatha SureclickEvolocumab11$10,484
Tresiba Flextouch U-100Insulin Degludec14$10,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,851
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$2,290
Pregabalin38$1,893
Diclofenac Sodium56$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$851$102,867142 claims
AmgenOtezla$309$57,89112 claims
AbbVieVraylar, Linzess$1,034$47,73735 claims
Lilly USA, LLCMounjaro$499$25,08020 claims
Novo NordiskOzempic$358$22,48020 claims
PfizerEliquis$154$19,88222 claims
Boehringer IngelheimJardiance$14$16,81322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Petersburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →